TheraRadar
← Back
Data updated: Jun 28, 2026

OTSUKA

Big Pharma
NeurologyCardiovascularDermatology Execution: Good

OTSUKA is a major pharmaceutical company focused on Neurology, Cardiovascular, Dermatology. Key products include ABILIFY MAINTENA KIT.

1997
Since
13
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
6 Small Molecules

FDA Novel Drug Designations

(2025)
1 Novel 1 First-in-Class 1 Breakthrough 1 Accelerated 1 Priority Review
See 1 novel approval →
2025 VOYXACT (SIBEPRENLIMAB-SZSI) First-in-Class · Breakthrough · Priority Review · Accelerated

OTSUKA at a Glance

  • Fast trial execution (20 months median completion)

OTSUKA's Recent FDA Approvals

OTSUKA secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

VOYXACT BLA
2025-11-25
sibeprenlimab-szsi
Immunoglobulin A Nephropathy

OTSUKA's Therapeutic Areas

OTSUKA's approved drugs and pipeline span 5 therapeutic areas, led by Neurology and Cardiovascular, across 0 biologic and 6 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 32%
1 drugs Phase 3: 16 Phase 2: 5 Phase 1: 1
Cardiovascular 26%
1 drugs Phase 3: 12 Phase 2: 4 Phase 1: 5
Dermatology 16%
0 drugs Phase 3: 8 Phase 2: 3 Phase 1: 3
Oncology 15%
1 drugs Phase 3: 1 Phase 2: 7 Phase 1: 15
Ophthalmology 11%
0 drugs Phase 3: 6 Phase 1: 3

OTSUKA's Top Competitors

OTSUKA's closest competitors by therapeutic-area and drug-target overlap include Bayer, Pfizer, and Novartis. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Bayer big-pharma
Oncology, Cardiovascular, Ophthalmology, Dermatology
Pfizer big-pharma
Oncology, Neurology, Dermatology
Novartis big-pharma
Oncology, Cardiovascular, Ophthalmology
FOUGERA PHARMS other
Dermatology, Ophthalmology, Oncology, Cardiovascular
Baxter specialty
Cardiovascular, Oncology, Dermatology

OTSUKA Pipeline Snapshot

OTSUKA has 89 active clinical programs from ClinicalTrials.gov — 43 Phase 3, 19 Phase 2 and 27 Phase 1.

43
Phase 3
19
Phase 2
27
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • ABILIFY MAINTENA KIT leads revenue
  • • 5 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Neurology pipeline focus
  • • Phase 3 readout tracking
View full pipeline →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 63/89 completed
  • • Speed: 20 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges